Acceptable Variability With Novel Sensor for Glucose Monitoring in T2D

FreestyleLibrePro glucose sensor
FreestyleLibrePro glucose sensor
One hundred fifteen patients used the FreeStyle Libre Pro sensor to monitor interstitial fluid glucose for 14 days.

Sensor glucose monitoring may be an acceptable alternative to traditional monitoring methods for patients with type 2 diabetes, according to research presented at the American Association for Nurse Practitioners (AANP) 2017 National Conference, held from June 20 to 25 in Philadelphia, Pennsylvania.

Davida F. Kruger, MSN, APN-BC, BC-ADM, from the Henry Ford Medical Center in Detroit, Michigan, and colleagues conducted a study examining glucose variability in patients with type 2 diabetes using the FreeStyle Libre Pro™ (Abbott Diabetes Care; Whitney, United Kingdom) investigational sensor glucose monitoring system. Primary study end point was glucose variability, as obtained by the sensor; secondary end points were assessment of patient ambulatory glucose profiles and participant questionnaires.

More than 100 (n=115) patients participated in the study (47% women; age, 59±11.5 years; body mass index, 34.2±6.8 kg/m2); those enrolled in the study had glycated hemoglobin (HbA1c) levels between 6% and 12% (42-108 mmol/mol) and were receiving American Diabetes Association/European Association for the Study of Diabetes-approved treatment (eg, metformin, sulfonylurea, glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor, or sodium-glucose cotransporter-2 inhibitor, among others).

Glucose variability was noted across all groups, irrespective of therapy type; increased variability was noted in patients using insulin or sulfonylurea therapy, but overall ambulatory glucose profiles were found to be “clinically acceptable.”

Overall, participants felt confident in the data collected by the glucose sensor. Specifically, patients in the 6.0% to 7.4% HbA1c group receiving sulfonylurea, basal insulin, or premixed insulin felt that the information presented in the sensor’s glucose reports contained enough information to “feel confident in making a change in therapy without the use of other data” such as blood glucose, meal, and exercise data (60%, 64%, and 88%, respectively). Patients with HbA1c levels from 7.5% to 12.0% undergoing dipeptidyl peptidase-4 inhibitor treatment were the only group to disagree with that statement, aside from participants not taking any medication.

Eleven percent of study participants experienced sensor insertion site symptoms. Additional adverse events included mild bleeding, edema, erythema, itching, and pain, with 19 occurrences in 13 participants.

Disclosures: Sponsorship for this study was provided by Abbott Diabetes Care.

Related Articles


Kruger DF, Mudyett K, Unger JR, Wright EE, Daniel TD, Henry RR. Assessment of glucose variability by professional glucose monitoring across therapy groups for type 2 diabetes. Presented at: American Association of Nurse Practitioners (AANP) 2017 National Conference; June 20-25, 2017; Philadelphia, PA.